CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Upadacitinib and Apremilast Combination Therapy for Guselkumab-Induced Paradoxical Eczema in Psoriasis
Jinan Dermatosis Prevention and Control Hospital, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Psoriasis is an immune-mediated inflammatory skin disease. Although biologics have markedly improved psoriasis symptoms, they may occasionally trigger paradoxical inflammatory reactions, particularly with IL-17A or TNF-α inhibitors. However, paradoxical inflammatory reactions associated with the IL-23 inhibitor guselkumab is exceptionally rare. We describe the case of a 70-year-old male with a 5-year history of psoriasis who had previously received tofacitinib for one year without achieving complete clearance. Following the initiation of guselkumab, the patient developed paradoxical eczema. Subsequent treatment with cyclosporine and the TYK2 inhibitor deucravacitinib proved ineffective. Ultimately, combination therapy with the JAK1 inhibitor upadacitinib and the PDE4 inhibitor apremilast achieved satisfactory control of both the paradoxical eczema and the underlying psoriatic lesions. This case highlights that upadacitinib used in combination with apremilast can effectively reverse paradoxical inflammatory reactions while sustaining psoriasis control. This dual-targeting strategy offers a novel therapeutic option for biologic-induced paradoxical reactions, and its broad-spectrum anti-inflammatory properties and potential synergistic effects warrant further clinical investigation.
Summary
Keywords
Apremilast, deucravacitinib, paradoxical reaction, Psoriasis, Upadacitinib
Received
31 August 2025
Accepted
03 April 2026
Copyright
© 2026 Yang, Zhou, Ruan and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhenqiang Ruan; Keshi Shi
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.